Johnson & Johnson is pursuing FDA and EMA investigation for Myelom management by Investing.com

RARITAN, NJ – Johnson & Johnson (NYSE:JNJ) has received a new indication from the US Food and Drug Administration (FDA) and the European Arzneimittel-Agentur (EMA) for DARZALEX FASPRO® (daratumumab and hyaluronidase drug) eingericht . The human soul on the treatment of the high smoldering multiple myeloma is a kind of active multiple myeloma. At Zulassung, DARZALEX FASPRO® was the first generic therapy for this patient group for the entire standard treatment.

Grundlage from Anträge since the Phase 3 Study AQUILA, the DARZALEX FASPRO® as Monotherapy in Erwachsenen with Hochriskiko-Smoldering-Multiplem-Myelom is not possible. This experience is clear that the underlying disease is in the knochenmark, but the typical symptom is that multiple myelomas are active. Bislang bestows the standard organization in the beobachtung to his fortification of illness. New knowledge you have received is a frühzeitige intervention patient with high risks for the treatment of active multiple myeloma.

Dr. Yusri Elsayed from Johnson & Johnson confirms that the DARZALEX is changing the treatment standard with Multiple Myelom. The Unternehmen department is now working on the disease of the FDA and EMA to treat patients with high-smoldering-multiplem myeloma, about which we have more information. The first part of the AQUILA study conducted during the American Society of Hematology (ASH) years was presented this month.

DARZALEX FASPRO® is intended for more indications in the treatment of multiple myelomas, both as monotherapy and in combination with other medications. This is a single CD38-targeted anti-treatment for patients with Multiplemic Myelom. The Swiss Partnership Janssen Biotech, Inc. and Genmab A/S which gives Janssen the exclusive Lizenz zur Entwicklung, Herstellung und Vermarktung von Daratumumab.

The press conference we have done is the use of the unused devices, switching on the potentials and handling sauces of DARZALEX FASPRO®, risks and uncertainties, which can improve the operation, which die tatsächlichen Ergebnisse wesentlich of the Erwartungen abweichen.

In other cases, Johnson & Johnson reported a large amount of cash with an associate at 6.3% on a collection of $22.5 billion. Das Unternehmen is highly aware of the prognosis for the family at the Mal in Folge. Moreover, the Bereich Innovative Medicine is worth 14 million US dollars in one of the most recent quarters.

In the course of the analyst upgrades, RBC Capital Markets has taken over the financial direction of Johnson & Johnson after these robust Ergebnissen have passed. RBC Capital Markets sees a price of US$178.00 to US$181.00, while Stifel sees a price of US$160 to US$170.

The first phase of treatment for the disease will be followed by the next Phase 3 GRAVITI trial of TREMFYA® (Guselkumab) in the treatment of Morbus Crohn. The study very, these patients, treated with TREMFYA®, lead to a clinical and endoscopic remission as a placebo works. Before the FDA approval with TREMFYA® the first IL-23 treatment for Morbus Crohn would undergo.

Everything seems to indicate that Johnson & Johnson has carried out lawful readmissions. The Unternehmen would have earned a value of 15 million dollars in a Talkum-Krebsfall, a while, that it is a woolen commotion.

InvestingPro Acknowledgment

Johnson & Johnson’s first response to a new indication of DARZALEX FASPRO® provides a strong position in the pharmaceutical industry. Laut InvestingPro-Daten gives J&Jüber a reasonable market capitalization of 377.35 billion US dollars, which was a modest price in general terms.

InvestingPro Tips have reformed J&J’s financial stability and consistent performance. The Unternehmen who had the dividend at 54 years in the Folge were very committed to active demonstrations. This follow-up is no longer relevant, the J&J production bot has developed a new market segment with DARZALEX FASPRO®.

J&Js Umsatzwachstum of 4.77% in the letzten-zwölf Monaten and a robust gross margin of 69.39% due to the underlying financial resources, a research and development initiatives involving the AQUILA study for the DARZALEX FASPRO® for use .

The fact is that J&J has moderate debt and has been pushing out its cash flows, a sense of debt. This financial overview can provide the new flexibility, one of the advantages of a new market instruction for the DARZALEX FASPRO® navigation.

Investors, the J&Js active in the company, may be interested in their inheritance, with InvestingPro 10 other tips for these business activities, which make a new analysis of the financial prosperity and market position of our internal economies.

This description can be performed by the intelligent intelligence. Weitere Informationen entnehmen Sie bitte unseren Nutzungsbedingungen.